US 7,105,499 B2 · Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

Abstract

The present invention provides nucleoside derivatives which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside derivatives alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside derivatives of the present invention.

Claims2

Dependent claims

A method of treating hepatitis C virus (HCV) infection comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of structural formula III, or a pharmaceutically acceptable salt or acyl derivatives thereof,

wherein B is
W is O or S;
Y is H, C1-10 alkylcarbonyl, P3O9H4, P2O6H3, or P(O)R9R10;
R1 is CF3, or C1-4 alkyl and one of R2 and R3 is OH or C1-4 alkoxy and the other of R2 and R3 is fluoro;
R6 is H, OH, SH, NH2, C1-4 alkylamino, di(C1-4 alkyl)amino, C3-6 cycloalkylamino, halogen, C1-4 alkyl, C1-4 alkoxy, or CF3;
R5 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-4 alkylamino, CF3, or halogen;
and
R9 and R10 are each independently hydroxy, OCH2CH2SC(═O)t-butyl, or OCH2O(C═O)iPr.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

10/250,873Filed 18 Jan 2002 · us provisional application

Priority

22 Jan 2001

Published

US 2004/0110717 A110 Jun 2004

Granted

12 Sep 2006

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61K 9/4858
Filling excipients; Inactive ingredients: organic compounds
A61K 31/7056
Having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides: containing five-membered rings with nitrogen as a ring hetero atom
A61K 31/7064
Containing six-membered rings with nitrogen as a ring hetero atom: containing condensed or non-condensed pyrimidines

Family

Application60/263,313Us provisional application · filed 22 Jan 2001

Application60/282,069Us provisional application · filed 6 Apr 2001

Application60/299,320Us provisional application · filed 19 Jun 2001

Application60/344,528Us provisional application · filed 25 Oct 2001

US 2004/0110717 A1Pre-grant publication · published 10 Jun 2004

US 7,105,499 B2This patent

From the US filing history. Foreign family members aren’t listed.

Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

Life of this patent

Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

Life of this patent

Abstract

Claims2